血友病
医学
凝血酶原复合物
骨科手术
血友病A
关节病
干预(咨询)
重症监护医学
外科
物理疗法
内科学
替代医学
凝结
骨关节炎
精神科
病理
作者
E. Carlos Rodríguez‐Merchán,Manuel Quintana,Víctor Jiménez‐Yuste
出处
期刊:Haemophilia
[Wiley]
日期:2008-09-29
卷期号:14 (s6): 56-67
被引量:13
标识
DOI:10.1111/j.1365-2516.2008.01891.x
摘要
Summary. Haemophilia patients with inhibitors commonly present much more severe musculoskeletal problems than patients without inhibitors. With haematological advances using recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (aPCC), it is now possible to perform orthopaedic procedures in these patients with a high rate of success. In Spain, the healthcare system sets no financial limits for the treatment of haemophilia, and children with haemophilia today have a much better musculoskeletal status than 30 years ago. However, the children of 30 years ago are now adults and are afflicted by severe articular deformities that frequently require the intervention of an orthopaedic surgeon. Our view is that the well‐known concepts of prophylaxis in patients without inhibitors should be followed and applied to patients with inhibitors. In fact, prophylaxis seems to be the only way to prevent the development of haemophilic arthropathy in patients with haemophilia. Until this goal can be achieved, major and minor orthopaedic procedures will be necessary in patients with inhibitors more frequently than in patients without inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI